An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 8, 2010, Pages 1529-1538

  Lepin, Eric J ^a   Leyton, Jeffrey V ^a   Zhou, Yu ^b   Olafsen, Tove ^a   Salazar, Felix B ^a   McCabe, Katelyn E ^a   Hahm, Scott ^a   Marks, James D ^b   Reiter, Robert E ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Cancer; Imaging; PET; Prostate; PSCA

Indexed keywords

IODINE 124; PROSTATE STEM CELL ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOACTIVE TRACERS;

EID: 77956187731     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1433-1     Document Type: Article

References (33)

1. KM Emonds JV Swinnen L Mortelmans FM Mottaghy 2009 Molecular imaging of prostate cancer Methods 48 193 199 10.1016/j.ymeth.2009.03.021 1:CAS:528:DC%2BD1MXmvFymtbw%3D 19362147
2. A Zaheer SY Cho MG Pomper 2009 New agents and techniques for imaging prostate cancer J Nucl Med 50 1387 1390 10.2967/jnumed.109.061838 1:CAS:528:DC%2BD1MXhtFOrtb3I 19690043
3. AM Wu 2009 Antibodies and antimatter: the resurgence of immuno-PET J Nucl Med 50 2 5 10.2967/jnumed.108.056887 1:CAS:528:DC%2BD1MXhvFCjt7w%3D 19091888
4. MK Haseman SA Rosenthal TJ Polascik 2000 Capromab Pendetide imaging of prostate cancer Cancer Biother Radiopharm 15 131 140 10.1089/cbr.2000.15.131 1:STN:280:DC%2BD3czpsVWmsw%3D%3D 10803318
5. MA Seltzer Z Barbaric A Belldegrun J Naitoh F Dorey ME Phelps, et al. 1999 Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 162 1322 1328 10.1016/S0022-5347(05)68277-8 1:STN:280:DyaK1MvhvF2gug%3D%3D 10492189
6. AB Raff A Gray WM Kast 2009 Prostate stem cell antigen: a prospective therapeutic and diagnostic target Cancer Lett 277 126 132 10.1016/j.canlet.2008. 08.034 1:CAS:528:DC%2BD1MXjslOktLc%3D 18838214
7. RE Reiter Z Gu T Watabe G Thomas K Szigeti E Davis, et al. 1998 Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer Proc Natl Acad Sci U S A 95 1735 1740 10.1073/pnas.95.4.1735 1:CAS:528: DyaK1cXht1WqurY%3D 9465086
8. Z Gu G Thomas J Yamashiro IP Shintaku F Dorey A Raitano, et al. 2000 Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer Oncogene 19 1288 1296 10.1038/sj.onc.1203426 1:CAS:528:DC%2BD3cXit1Krsb0%3D 10713670
9. JS Lam J Yamashiro IP Shintaku RL Vessella RB Jenkins S Horvath, et al. 2005 Prostate stem cell antigen is overexpressed in prostate cancer metastases Clin Cancer Res 11 2591 2596 10.1158/1078-0432.CCR-04-1842 1:CAS:528: DC%2BD2MXivFKisrc%3D 15814638
10. N Amara GS Palapattu M Schrage Z Gu GV Thomas F Dorey, et al. 2001 Prostate stem cell antigen is overexpressed in human transitional cell carcinoma Cancer Res 61 4660 4665 1:CAS:528:DC%2BD3MXks1GrtL4%3D 11406532
11. P Argani C Rosty RE Reiter RE Wilentz SR Murugesan SD Leach, et al. 2001 Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma Cancer Res 61 4320 4324 1:CAS:528:DC%2BD3MXktlSqurs%3D 11389052
12. DM McCarthy A Maitra P Argani AE Rader DO Faigel NT Van Heek, et al. 2003 Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases Appl Immunohistochem Mol Morphol 11 238 243 1:CAS:528:DC%2BD3sXntFSntr8%3D 12966350
13. T Olafsen Z Gu MA Sherman JV Leyton ME Witkosky JE Shively, et al. 2007 Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody J Immunother 30 396 405 10.1097/CJI.0b013e318031b53b 1:CAS:528:DC%2BD2sXksFOlsbg%3D 17457214
14. JV Leyton T Olafsen EJ Lepin S Hahm KB Bauer RE Reiter, et al. 2008 Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Clin Cancer Res 14 7488 7496 10.1158/1078-0432.CCR-07- 5093 1:CAS:528:DC%2BD1cXhtlylurzE 19010866
15. K Fujimori DG Covell JE Fletcher JN Weinstein 1990 A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J Nucl Med 31 1191 1198 1:STN:280:DyaK3czgtVensg%3D%3D 2362198
16. D Colcher MF Minelli M Roselli R Muraro D Simpson-Milenic J Schlom 1988 Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies Cancer Res 48 4597 4603 1:STN:280: DyaL1c3ot1eqtQ%3D%3D 3396011
17. J Schlom D Eggensperger D Colcher A Molinolo D Houchens LS Miller, et al. 1992 Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates Cancer Res 52 1067 1072 1:CAS:528:DyaK38XhvFSgsrs%3D 1310638
18. MP Velders CM van Rhijn IH Briaire GJ Fleuren SO Warnaar SV Litvinov 1995 Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model Cancer Res 55 4398 4403 1:STN:280:DyaK2MvgtFajuw%3D%3D 7671252
19. I Verel KH Heider M Siegmund E Ostermann E Patzelt M Sproll, et al. 2002 Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts Int J Cancer 99 396 402 10.1002/ijc.10369 1:CAS:528:DC%2BD38XjsFagtbw%3D 11992408
20. GP Adams R Schier AM McCall HH Simmons EM Horak RK Alpaugh, et al. 2001 High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules Cancer Res 61 4750 4755 1:CAS:528:DC%2BD3MXks1Grtbs%3D 11406547
21. UB Nielsen GP Adams LM Weiner JD Marks 2000 Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity Cancer Res 60 6434 6440 1:CAS:528: DC%2BD3cXos1SktLo%3D 11103810
22. ET Boder KS Midelfort KD Wittrup 2000 Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity Proc Natl Acad Sci U S A 97 10701 10705 10.1073/pnas.170297297 1:CAS:528:DC%2BD3cXnt1aiuro%3D 10984501
23. KS Midelfort HH Hernandez SM Lippow B Tidor CL Drennan KD Wittrup 2004 Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody J Mol Biol 343 685 701 10.1016/j.jmb.2004.08.019 1:CAS:528:DC%2BD2cXot1WrtL4%3D 15465055
24. CP Graff K Chester R Begent KD Wittrup 2004 Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C Protein Eng Des Sel 17 293 304 10.1093/protein/gzh038 1:CAS:528:DC%2BD2cXntFagt74%3D 15115853
25. A Razai C Garcia-Rodriguez J Lou IN Geren CM Forsyth Y Robles, et al. 2005 Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A J Mol Biol 351 158 169 10.1016/j.jmb.2005.06.003 1:CAS:528:DC%2BD2MXmt1Wgs7c%3D 16002090
26. N Craft C Chhor C Tran A Belldegrun J DeKernion ON Witte, et al. 1999 Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process Cancer Res 59 5030 5036 1:CAS:528:DyaK1MXmslWkur0%3D 10519419
27. AM Wu PJ Yazaki S Tsai K Nguyen AL Anderson DW McCarthy, et al. 2000 High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment Proc Natl Acad Sci U S A 97 8495 8500 10.1073/pnas.150228297 1:CAS:528:DC%2BD3cXlt1Ggu7Y%3D 10880576
28. Y Zhou DC Drummond H Zou ME Hayes GP Adams DB Kirpotin, et al. 2007 Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells J Mol Biol 371 934 947 10.1016/j.jmb.2007.05.011 1:CAS:528:DC%2BD2sXot12rtb8%3D 17602702
29. RD Gietz RH Schiestl 1991 Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier Yeast 7 253 263 10.1002/yea.320070307 1:CAS:528:DyaK3MXktVCqtLY%3D 1882550
30. T Olafsen VE Kenanova AM Wu 2006 Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment Nat Protoc 1 2048 2060 10.1038/nprot.2006.322 1:CAS:528:DC%2BD2sXhtFagtrvO 17487194
31. V Kenanova T Olafsen DM Crow G Sundaresan M Subbarayan NH Carter, et al. 2005 Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments Cancer Res 65 622 631 1:CAS:528:DC%2BD2MXns1Oisg%3D%3D 15695407
32. AM Loening SS Gambhir 2003 AMIDE: a free software tool for multimodality medical image analysis Mol Imaging 2 131 137 10.1162/153535003322556877 14649056
33. MK Gagnon SH Hausner J Marik CK Abbey JF Marshall JL Sutcliffe 2009 High-throughput in vivo screening of targeted molecular imaging agents Proc Natl Acad Sci U S A 106 17904 17909 10.1073/pnas.0906925106 1:CAS:528: DC%2BD1MXhtl2rurvI 19815497